VivoSim Labs, Inc. (VIVS) 株式分析

企業概要

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that specializes in the testing of drugs and drug candidates using three-dimensional human tissue models focused on the liver and intestine. The firm provides its partners with critical liver and intestinal toxicology insights through its novel approach methodologies (NAM) models, which facilitate a more physiologically relevant assessment of drug safety. Operating within the Healthcare sector and specifically the Biotechnology industry, the company leverages advanced tissue engineering to support the drug development pipeline. The firm currently maintains a market capitalization of $4.57M, with annual revenue of $142,000 and an employee base of 14 individuals. These valuation and revenue figures indicate that the company operates as a micro-cap entity with a very small revenue footprint relative to its market capitalization, suggesting a stage where valuation is driven more by potential future utility than current earnings power.

財務健全性

The company reported a revenue of $142,000 for the trailing twelve months, yet recorded a net income of $-1,227,000 and an EBITDA of $-11,221,000. The substantial gap between the positive revenue of $142,000 and the significant net loss of $-1,227,000 reveals a cost structure characterized by high operating expenses that far exceed current income generation, which is typical for early-stage biotechnology firms. Free cash flow stands at $-7,895,875, indicating that the company is burning through cash reserves rather than generating liquidity, which limits its immediate financial flexibility for capital expenditures or strategic acquisitions without external funding. The gross margin is listed at 0.0%, while the operating margin is -10576.9% and the profit margin is 0.0%; these figures collectively indicate that the company is incurring losses on every dollar of sales and has not yet achieved profitability on an operational or net basis. On the balance sheet, the company holds $4.29M in cash against $812,000 in debt, resulting in a debt-to-equity ratio of 18.28. Despite the relatively high debt-to-equity multiple, the significant cash balance suggests the company has ample liquidity to service its obligations, though the ratio itself implies a leveraged position relative to equity. The current ratio of 2.44 indicates that the company holds sufficient current assets to cover its current liabilities more than twice over, pointing to a robust short-term liquidity position. Furthermore, the return on equity is -51.1% and the return on assets is -132.5%, metrics that reveal that management is currently eroding shareholder value and utilizing assets inefficiently in terms of generating positive returns.

バリュエーション評価

The trailing twelve-month P/E ratio is 0.90, while the forward P/E is N/A, implying that the market does not currently expect normalized earnings growth that would result in a meaningful forward multiple. The price-to-book ratio is 0.93, indicating that the stock is trading at a slight discount to its book value, which suggests the market is not applying a significant premium to the company's tangible assets. The price-to-sales ratio stands at 32.21 and the EV/EBITDA is -0.06, suggesting that the market is valuing the company based on sales multiples rather than earnings, a common practice for unprofitable firms, while the negative EV/EBITDA reflects the company's deep losses. The 52-week high is $5.30 and the 52-week low is $1.25, meaning the current trading price sits within a range defined by these extremes, though the specific current price is not provided to calculate an exact percentage deviation. The beta value is 1.44, which indicates that the stock's price volatility is expected to be 44% higher than the broader market, making it a high-risk investment for risk-averse portfolios.

Growth & Income

Revenue growth year-over-year is 8.3%, whereas earnings growth is N/A due to the company's lack of profitability. Since the earnings growth rate is not applicable, the revenue growth does not translate into profit improvement at this stage, implying that top-line expansion is not yet sufficient to cover the underlying cost structure. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, indicating that it reinvests any available resources and retains earnings into growth initiatives rather than paying out income to shareholders. The overall growth and income profile characterizes a high-risk, high-volatility instrument with no current income generation, relying entirely on future operational success to achieve profitability and sustainable cash flow.